Cardiff Oncology Inc expected to post a loss of 23  cents a share - Earnings Preview

Cardiff Oncology

02/05/2022 12:06

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 4
(estimated). 
    * The San Diego California-based  company is expected to
report  a
34.5% decrease in revenue to $47.17 thousand from $72 thousand a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cardiff Oncology
Inc is
for a loss of 23 cents per share. For the same quarter last
year, the company reported a loss of 14 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $17​, above​ its last closing price of $1.34. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.17       -0.17      -0.23     Missed  -34
 Sep. 30 2021  -0.17       -0.17      -0.17     Met     0
 Jun. 30 2021  -0.15       -0.15      -0.17     Missed  -13.5​
 Mar. 31 2021  -0.16       -0.15      -0.14     Beat    5.1
 ​​Dec.        -0.15       -0.14      -0.19     Missed  -35.7
 31 2020                                                
 Sep. 30 2020  -0.19       -0.19      -0.19     Met     -1.8​
 Jun. 30 2020  -0.24       -0.24      -0.51     Missed  -112.5
 This summary was machine generated May 2 at 11:06 GMT.  All
figures in US dollars  unless otherwise stated